Today: 1 July 2026
Browse Category

Pharmaceutical Industry 7 December 2025 - 16 December 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a steady drumbeat of pipeline and regulatory updates heading into 2026. Smartkarma While BMY has spent much of the past year wrestling with familiar big-pharma headwinds—generic erosion in legacy products and a looming “patent cliff” narrative—the last several weeks have looked more like a sentiment reset than a victory lap. One analysis notes a ~16% move over the last 30 days alongside renewed investor focus on late-stage pipeline and strategic deals. Simply Wall St
16 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb Company is ending Monday’s session in the spotlight after a sharp, analyst-driven move that pushed the pharma giant higher into the close — and kept the shares firm in extended trading. After the closing bell on Monday, December 15, 2025, BMY was up about 3.6% in regular trading and added roughly another 0.6% after hours, as investors digested a bullish call from Bank of America and looked ahead to a potentially volatile macro catalyst before Tuesday’s open. MarketWatch
16 December 2025
··
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Inc. enters the new week with its stock hovering around $25.85 in early Monday trading, as investors weigh a familiar late-2025 mix: a high dividend, a rebuilding growth story after the COVID boom, and a pipeline/M&A strategy designed to refill the revenue engine ahead of major patent cliffs. The immediate spotlight is tomorrow morning’s full-year 2026 guidance call—a scheduled catalyst that can reset expectations for revenue, margins, and capital allocation going into 2026. Pfizer
15 December 2025
····
Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals Inc. entered a new phase in its corporate life this month: from clinical-stage story stock to a company with an FDA-approved, commercially launchable cardiovascular product. The catalyst is CARDAMYST™ nasal spray, now approved in the U.S. for adults experiencing acute symptomatic episodes of paroxysmal supraventricular tachycardia—a rapid heart rhythm disturbance that can be frightening, disruptive, and costly when it sends patients to emergency care. GlobeNewswire Yet in classic biotech fashion, the stock market’s reaction has been anything but simple. Despite the “yes” from regulators, MIST shares saw sharp volatility into the weekend, and investors are now shifting focus from approval risk to the harder, longer game: commercial execution. Nasdaq+1
15 December 2025
·
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited shares closed Friday at A$183.93, ending a volatile week only slightly lower overall after a sharp rebound into the weekend. Investors are weighing two very different storylines at once: encouraging long-term clinical data for CSL’s hemophilia B gene therapy HEMGENIX, and fresh scrutiny on Australia’s onshore vaccine manufacturing deals tied to CSL Seqirus — all while CSL continues to steadily mop up stock through its A$750 million on-market buyback. Global Newsroom | CSL+4Yahoo Finance+4Intelligent Investor+4 Below is what moved CSL this week, the most important news in the last few days, and what to watch in the week ahead.
14 December 2025
··
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences Corp. is back in the spotlight on Friday, December 12, 2025, after European regulators recommended refusing marketing authorization for Blarcamesine Anavex in Alzheimer’s disease—an outcome that investors had been bracing for since last month’s negative “trend vote” from the EMA’s scientific committee. European Medicines Agency+1 The regulatory news hit a stock that has already been trading like a “binary event” biotech: high volatility, heavy short interest, and a valuation that depends largely on the probability of eventual approval and/or additional pivotal evidence in neurodegenerative indications. Finviz+1
12 December 2025
·
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

As of December 11, 2025, Pfizer Inc. is trying to rewrite its post‑COVID story. The stock trades around $25.66 per share, after a choppy year of guidance upgrades, obesity-drug M&A, aggressive cost cuts and fresh regulatory wins in oncology and rare disease. Since November 21, 2025, a cluster of headlines — from an FDA approval in bladder cancer to a new GLP‑1 weight‑loss deal and expanding cost‑saving measures — has shifted how analysts and investors think about Pfizer’s earnings power going into 2026 and beyond.
11 December 2025
·
Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Updated: December 11, 2025 – all figures and ratings as of publication; this article is for information only and is not investment advice. Wave Life Sciences Ltd., a clinical‑stage biotechnology company focused on RNA‑based medicines, has gone from relative obscurity to market headline in a matter of days.
11 December 2025
···
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics, Inc. is back center stage on December 11, 2025, as traders digest a fresh equity offering, strong late‑stage clinical data, and a newly filed Biologics License Application for its lead drug, atacicept, in IgA nephropathy. During Thursday’s session, VERA shares were trading around $46, up roughly 3–4% on the day and near 52‑week highs, leaving the company with a market capitalization of about $2.9–3.0 billion.Stock Titan
11 December 2025
·
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer Inc. finished a volatile Tuesday session on December 9, 2025 under pressure, then stabilized in after-hours trading as investors digested a big new obesity-drug licensing deal and fresh headlines around RSV therapies. With the next U.S. market session opening on December 10, 2025, traders in Pfizer stock are lining up the key catalysts that could drive PFE’s next move. During regular trading on December 9, Pfizer shares slipped again:
10 December 2025
····
Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

As of Tuesday, December 9, 2025, Eli Lilly sits at the center of nearly every conversation about obesity drugs, oncology breakthroughs and “next trillion‑dollar” stocks. The shares trade around $980 per share, down about 1.6% on the day but still roughly 57% above their 52‑week lowand about 12% below the recent record high of $1,111.99 set in late November.StockAnalysis+1 That puts Lilly’s market value in the high‑$800 billion range, after briefly crossing $1 trillion in market cap on November 21, the first pharmaceutical company ever to do so.Reuters+2EMARKETER+2
9 December 2025
·
Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

December 9, 2025 — Dyne Therapeutics, Inc. shares were volatile on Tuesday, giving back part of a recent rally even as Wall Street responded positively to new clinical data and raised price targets on the neuromuscular‑disease biotech. In early afternoon U.S. trading, Dyne stock was changing hands around $19.15, down roughly 14% on the day after opening near $21.41 and moving in a range between about $19 and $22. The pullback follows a sharp advance on Monday, when the shares jumped high‑single‑digits after the company released detailed positive Phase 1/2 results from its DELIVER trial in Duchenne muscular dystrophy. StockInvest+3GlobeNewswire+3Nasdaq+3
9 December 2025
··
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering and a wave of fresh analyst price‑target hikes.GlobeNewswire+3Investing.com+3Investing.com+3
9 December 2025
····
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after the company unveiled strong mid‑stage data for its once‑daily oral GLP‑1 obesity pill, aleniglipron. GlobeNewswire+2Investors+2 Over the past six months, GPCR has already delivered a multi‑bagger move, with one analyst note calculating a ~241% gain even before today’s opening bell. The stock now sits near its 52‑week high, with a 52‑week range of about $13.22 to $94.90 and a market capitalization around $4.0 billion. Investing.com+2MarketBeat+2
9 December 2025
··
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about $18.52 per share, pushing the company’s market cap to around $3.0 billion as of early December 9. MLQ At the same time, Wave launched a $250 million public equity offering, setting up a dramatically stronger balance sheet—but also introducing dilution right after the rally. GlobeNewswire
9 December 2025
···
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics, Inc. delivered one of the biggest biotech moves on Wall Street today. On Monday, December 8, 2025, Kymera stock surged more than 40% intraday, trading around $96 late in the session after touching an intraday high above $100, on volume far above normal. MarketBeat The catalyst: very strong Phase 1b data for KT‑621, a once‑daily oral STAT6 degrader for atopic dermatitis and broader Type 2 inflammatory diseases. GlobeNewswire
8 December 2025
··
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron, a once‑daily oral GLP‑1 receptor agonist for obesity. The market response was immediate: GPCR closed at $69.46, up about 101% on the day, after trading between $24.83 and an intraday high of $94.90.
8 December 2025
···
AbbVie Stock (ABBV) Today: Price, Dividend Hike, Pipeline Catalysts and 2025–2026 Outlook

AbbVie Stock (ABBV) Today: Price, Dividend Hike, Pipeline Catalysts and 2025–2026 Outlook

AbbVie’s stock is trading just below record highs as investors digest a powerful mix of rising earnings, a fresh dividend increase and a steady drumbeat of positive pipeline news in immunology, neuroscience and oncology. As of the close on Friday, December 5, 2025, AbbVie finished at $226.08, down about 1.15% on the day and roughly 7–8% below its 52‑week high of $244.81 set on October 1.MarketWatch+1 That still leaves the company with a market capitalization around $400 billion, firmly placing it among the largest healthcare stocks globally.The Motley Fool+1
7 December 2025
···
1 … 5 6 7 8 9

Stock Market Today

  • Geiger Counter Ltd Buys Back 19,069 Shares at 63.95p Each
    July 1, 2026, 4:59 AM EDT. Geiger Counter Ltd repurchased 19,069 ordinary shares on June 30, 2026, paying an average of 63.95 pence per share. That price is about a 7% discount to fully diluted value. The company said the shares go into Treasury as part of an ongoing program. Since March 11, 2026, the group has repurchased 7,392,222 shares under the plan. After this buyback, Geiger Counter has 173,641,396 ordinary shares outstanding, with 118,410,966 voting shares and 55,230,430 in Treasury. The company said the buybacks are meant to keep capital structure and shareholder value on track.
Go toTop